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Abstract:  Oral delivery is the most common and preferred route of drug administration 
although the digestive tract exhibits several obstacles to drug delivery including motility 
and intraluminal pH profiles.  The gut milieu represents the largest mucosal surface 
exposed to microorganisms with 1010-12 colony forming bacteria/g of colonic content.  
Approximately, one third of fecal dry matter is made of bacteria/ bacterial components.  
Indeed, the normal gut microbiota is responsible for healthy digestion of dietary fibers 
(polysaccharides) and fermentation of short chain fatty acids such as acetate and butyrate 
that provide carbon sources (fuel) for these bacteria.  Inflammatory bowel disease (IBD) 
results in breakage of the mucosal barrier, an altered microbiota and dysregulated gut 
immunity.  Prodrugs that are chemically constructed to target colonic release or are 
degraded specifically by colonic bacteria, can be useful in the treatment of IBD.  This 
review describes the progress in digestive tract prodrug design and delivery in light of gut 
metabolic activities. 
 
Keywords: Inflammatory bowel disease, Digestive tract, Drug delivery, microbiota, 
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Introduction 
 
Oral delivery is the most common and preferred route of drug administration. This is the ideal 
route to deliver compounds to colonic sites to treat Inflammatory Bowel Disease (IBD); however; the 
digestive tract exhibits several obstacles to drug delivery including gut motility [1-2], stomach and 
intraluminal pH profiles, and degradative enzymes [3].  Therefore, prodrugs are designed to transport 
intact drug through the stomach and small intestine, but be hydrolyzed by the colonic microbiota to 
release the active compound.    
The concept of “prodrug” was first introduced by Adrien Albert in 1958 [4] to describe compounds 
that undergo biotransformation prior to eliciting their pharmacological effect, i.e. "therapeutic agents 
that are inactive but transform into one or more active metabolites." Prodrugs are designed to 
overcome pharmaceutical, pharmacokinetic, or pharmacodynamic barriers such as insufficient 
chemical stability, poor solubility, unacceptable taste or odor, irritation or pain, insufficient oral 
absorption, inadequate blood-brain barrier permeability, marked pre-systemic metabolism, and toxicity 
[5]. Furthermore, by attachment of a pro-moiety to the active moiety, a prodrug is formed which is 
designed to overcome the barriers that hamper the optimal use of the active principle [6]. 
The prodrug approach, in which a derivative of the active compound is synthesized, has been 
proven to be an effective and important way of overcoming barriers that restrict the application of 
many chemical entities as orally administered drugs [7-8].  The colonic drug delivery systems are 
mainly based on degradation of a prodrug by microorganisms of the colon flora [9-10] and colonic 
enzymes [11-12].  In this review different approaches to colonic drug delivery are discussed.  
 
Inflammatory Bowel Disease  
 
IBD refers to idiopathic inflammatory diseases of the intestine, principally ulcerative colitis and 
Crohn’s disease [13].  IBD is characterized by chronic inflammation in the mucosal membrane of the 
small and/or large intestine. Although many treatments have been recommended for IBD, they do not 
treat the cause but are effective only in reducing the inflammation and accompanying symptoms in up 
to 80% of patients. Thus, current medical management of IBD consists of anti-inflammatory and 
immunosuppressive agents and biologic drugs, as well as surgery [13-15].  The mortality rate of patients 
with Crohn’s disease is 40% greater than those without evidence of disease including Ulcerative 
disease [14].  In a retrospective, population based cohort study of mortality by medication use among 
IBD included 9032 patients during 1996-2002; with the exception of immunomodulators, the 
medications for IBD were not significantly associated with mortality among IBD patients. However, 
infections, respiratory diseases and digestive diseases other than IBD have been important specific 
cause of death in IBD patients.  Despite medical intervention, many patients with IBD suffer from 
complications including abscesses, fistulae, intestinal obstruction, chronic blood loss, and intestinal 
neoplasia.  Also, colorectal cancer is increased in IBD, particularly among male patients [14]. 
Recent research has lead to the development of several new treatment strategies that target specific 
biomolecules.  There are multiple therapies in various stages of investigation, including biological agents 
such as human recombinant cytokines IL-10 [16], IL-11, IL-12 [17-18] and antisense oligonucleotides to 
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intercellular adhesion molecule (ICAM), α4 integrin [19], and monoclonal antibodies to TNF-α [19-20] 
and IFN-γ with many more on the horizon. Although these approaches are exciting and represent a move 
forward in the treatment of IBD, several issues remain. These include cost, long-term safety, adverse 
effects, and the requirement for a parenteral route of administration. Finally, many IBD patients remain 
refractory or intolerant to current therapies.   
 
Pathogenesis of IBD  
 
The etiology of IBD remains unknown; however, two primary theories have been proffered focusing 
on either a specific persistent infectious agent [21-22] or an abnormal host immune response to 
ubiquitous antigens in the luminal constituents.  Evidence supports that patients with IBD are genetically 
susceptible to this disease, and the defect targets an inability to effectively down-regulate the 
inflammatory response to specific antigens or luminal bacteria [23]. Genetically engineered animals 
develop spontaneous enterocolitis that resembles IBD [24].  In several of these models (e.g. IL-2-/-, IL-
10-/- mice, HLA-B27 transgenic rats), the normal resident bacterial microbiota is necessary for the 
development of colitis [25-26]. These data suggest that in a genetically susceptible host, a dysregulated 
inflammatory/immune response to the nonpathogenic luminal commensal bacteria leads to a chronic 
inflammatory process.  Inflammatory responses in the intestine can be induced by disorders of 
immunoregulation, infectious colitis, impaired circulation, or even toxic compounds.   
Striking similarities exist in the clinical and morphologic manifestations among these various forms 
of intestinal inflammation.  These similarities probably do not reflect directed target cell injury but rather 
innocent bystander effects due to the presence of soluble mediators of inflammation [27]. These 
mediators include reactive oxygen species (ROS), cytokines, arachidonic acid metabolites, and growth 
factors.  Cytokines also elicit numerous metabolic responses including altered zinc metabolism [28], and 
synthesis of acute phase reactants that also are biochemical/clinical complications of IBD [29].  In 
addition, neutrophil and macrophage infiltration suggest the presence of chemotaxins in the mucosal 
tissues.  Mucosal edema and hyperemia reflect the presence of soluble mediators that induce vascular 
permeability and vasodilatation [30].  
 
LPS and TNF production and IBD 
 
The gut milieu represents the largest mucosal surface exposed to microorganisms with 1010-12 
colony forming bacteria/g of colonic content.  The intestinal micobiota [31] represents 400–500 
bacterial species, and encompasses more bacterial cells than eukaryotic cells within the human body 
[32].  Approximately, one third of fecal dry matter is made of bacteria/ /bacterial components. Indeed, 
the normal gut microbiota is responsible for healthy digestion of dietary fibers (polysaccharides) and 
fermentation of short chain fatty acids such as acetate, butyrate and propionate that provide carbon 
sources (fuel) for these bacteria, nutrient production, metabolism of dietary carcinogens, and 
conversion of prodrugs to active drugs.  However, growing evidence suggests that the enteric 
microorganisms are critical components in the pathogenesis of IBD and bacterial endotoxemia has 
been postulated to play a key role in IBD [23, 32].   
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Bacteroides and Clostridium species have been specifically implicated with inflammatory 
responses in different animal models of IBD [21,23], whereas other commensals such as Lactobacillus 
and Bifidobacterium species, have minimal proinflammatory capabilities and are less likely to 
translocate from the lumen to the internal milieu [23].  Lipopolysaccharide (LPS), a cell wall 
constituent of Gram-negative bacteria, is present in a high concentration in the normal colonic lumen. 
When exposed to LPS, or other stimuli, macrophages release a variety of mediators of inflammation, 
of which TNF-α is a prominent component that mediates some disparate effects of LPS challenge [33]. 
TNF-α is produced earlier than some other cytokines after an LPS challenge and comprises ~2% of the 
total secretory products made by activated macrophages [34]. In LPS-treated animals, TNF-α achieves 
peak serum concentrations 60-120 minutes after LPS administration. ROS generated during IBD are 
also important stimuli for TNF-α production.  Administration of purified TNF-α to animals evokes the 
same metabolic response as LPS, including fever, anorexia, neutrophilia, and muscle wasting. These 
biochemical/clinical complications are also present in IBD [29]. In addition, endotoxemia and elevated 
serum concentrations of inflammatory cytokines, including TNF-α, are observed in IBD patients [35]. 
In these cases, injury is down-regulated by antibody to TNF-α [19-20, 36].   
 
NF-κB and IBD   
 
As a transcriptional activator of genes encoding inflammatory cytokines and adhesion molecules, 
NF-κB is an important effector molecule in intestinal inflammation and also a suitable target for anti-
inflammatory therapy. Mucosal inflammation in clinical IBD has been linked to the upregulated 
nuclear translocation of the pro-inflammatory transcription factor complex NF-κB and expression of 
pro-inflammatory cytokines, such as TNF-α. Multiple stimuli, including ROS, cytokines and endotoxin, 
cause release of IκB and permit NF-κB to enter the nucleus, bind to DNA control elements, and induce 
transcription of specific genes (e.g. mediators of inflammation in IBD). These include cytokines (e.g. IL-
1, 6, 8, 12, and TNF-α), enzymes (e.g. inducible nitric oxide synthase), and cell adhesion molecules (e.g. 
E-selectin) [37]. Several established anti-inflammatory and immunosuppressive agents used in the 
treatment of IBD are known inhibitors of NF-κB.  For instance, glucocorticoids block NF-κB activity in 
part by upregulating IκB protein levels [38-39]. Sulfasalazine [40] mesalamine [41] and Cyclosporin A, 
all immunosuppressants that target T cells, also inhibit NF-κB [42].  
 
Reactive Oxygen Species (ROS) 
 
Oxidant-mediated injury plays an important role in the pathophysiology of IBD. ROS upregulate 
NF-κB and result in further increases in the levels of oxidants and tissue injury in IBD.  Inflamed gut 
from IBD patients, as well as IBD animal models, are rich in activated macrophages and neutrophils 
and these inflammatory cells generate excess amounts of ROS with subsequent increases in oxidative 
stress [43]. These ROS include hydroxyl radicals, superoxide anions, hydrogen peroxide, and nitric 
oxide.  ROS are extremely unstable species due to their high reactivity and may result in lipid 
peroxidation and the oxidation of DNA and proteins [44]. The increased generation of highly toxic 
ROS exceeds the limited intestinal antioxidant defense system, thereby contributing to intestinal 
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oxidative injury in IBD patients [45]. Excessive production of ROS has been demonstrated in 
circulating phagocytic and polymorphonuclear leukocytes in IBD patients using a chemiluminescence 
assay [46-47] and following stimulation with the bacterial chemotactic peptide N-formyl-methionyl-
leucyl-phenylalanine (fMLP) [48].  Thus, oxidant-mediated injury plays an important role in the 
pathophysiology of IBD.  
 
The Prodrug Approach 
 
The primary goal of drug therapy in IBD is to reduce inflammation in the colon that generally 
requires frequent intake of high dose anti-inflammatory drugs. Thus, the prodrug approach continues to 
provide increased scrutiny as an alternative to this systemic approach.   Three classes of Prodrugs, 
which target drug to the colon are currently used in IBD or are in experimental stages: (1) Anti-
inflammatory agents (eg. azu prodrugs, 5-Aminosalicylic acid, amino acids) that can result from 
bacteria changing the function of prodrugs or prodrugs treating inflammation which changes the 
bacterial ecology; (2) Immunomodulators and Immunosuppressants; and, (3) Antioxidants. 
 
Anti-Inflammatory Prodrugs: 
  
5-Aminosalicylic acid 
 
5-Aminosalicylic acid (5-ASA, 1a, Figure 1) is an effective compound to attenuate the 
inflammatory response in IBD while its mechanism of action is not fully understood.  Thus, it usually 
fails to reach the colon leading to significant adverse effects such as ulcerogenic potential [49]. 
Therefore, a prodrug approach for colonic delivery of 5-ASA has become a rational system of drug 
delivery for the topical treatment of IBD. 5-ASA triggers the peroxisome proliferator-activated 
receptor (PPAR-γ) family of nuclear receptors, which regulate inflammation, cell proliferation, 
apoptosis, and metabolic function. PPAR-γ receptors are highly expressed in colonic epithelia and their 
expression is upregulated by the gut bacteria [50].  
 
Figure 1. (1a) Molecular structure of 5-Aminosalicylic acid (5-ASA); (1b)  Molecular 
structure of Sulfasalazine (5-ASA linked to Sulfapyridine by the azo bond). 
OH
COOH
NH2
N
NOH
HOOC
N SO2 N
1a: 5-ASA
1b: Sulfasalazine  
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In order to achieve an effective colonic delivery, a drug needs to be protected from absorption 
and/or the environment of upper GI tract and then rapidly released into the proximal colon, which is 
the optimalsite for colon-targeted delivery of the drug. Colonic drug delivery through colon-specific 
prodrug activation may be accomplished by the utilization of the high activity of certain enzymes at 
the target site relative to non-target tissues, enabling for prodrug conversion to active drug [51]. 
The microbiota of the GI tract consists of a coexisting mixture of aerobic, facultative anaerobic, 
and strict anaerobic bacteria in a complex ecosystem. These bacteria produce a wide range of enzymes, 
such as β-glucuronidase, β-xylosidase, α-arabinosidase, β-galactosidase, nitroreductase, azoreductase, 
deaminase, urea hydroxylase, etc [52]. The reductive environment of the bacterial microbiota can be 
utilized for colon targeting.  The prodrug approach has been successfully utilized with sulfasalazine 
(an azo prodrug 5-ASA and sulfapyridine, 1b, Figure 1) for targeting drugs to the colon [51].  The azo 
prodrugs are poorly absorbed in the stomach and small intestine. The azo linkage is cleaved by the 
azoreductases released by the colonic anaerobic bacteria to form a pair of amines [53].   The majority 
of side effects of sulfasalazine, eg. hepatotoxicity, hypospermia, and severe blood disorders, are due to 
sulfapyridine. Even though different prodrugs of 5-ASA like balsalazide, ipsalazine and olsalazine [9-
11] have been reported, few of them have extended beyond the stage of clinical trials. 
Balsalazide, a prodrug of 5-ASA and an analogue of sulfasalazine, is linked to the carrier 4-
aminobenoyl β-alanine via an azo-bond and is specifically converted to 5-ASA by azo-reducing 
bacteria present in the colon [54].  The prodrug remains intact in the gastrointestinal tract until it 
reaches the colon.  This agent uses a mode of drug administration to exert a local anti-inflammatory 
effect directly on the inflamed lining of the intestinal wall.  Alternatively to colon targeting, many 
prodrug projects are directed toward avoiding gastrointestinal side effects.  Olsalazine is a dimer of 5-
ASA linked by an azo-bond to avoid the sulfapyridine moiety [9-11]. The slow release 5-ASA 
preparations (enteric-coated; eg. mesalamine, Pentasa, Asacol) have been approved by the FDA.  
Pentasa microgranules are coated with a semipermeable membrane of ethylcellulose with amphoionic 
properties. 5-ASA is slowly released over time from the granules into the intestine, and enhanced with 
pH above 6.0. [55].   However, the need for a safer, colonic delivery of prodrugs of 5-ASA with 
nontoxic carriers and non- ulcerogenic potential still remains. 
Still in an exploratory stage, recently an amino acid (mutual) azo prodrug of 5-ASA was 
synthesized by coupling L-tryptophan with salicylic acid, for targeted drug delivery to the inflamed 
colonic tissue in IBD [56]. The structure of the synthesized prodrug was confirmed by elemental 
analysis, IR and NMR spectroscopy. In vitro kinetic studies showed negligible release of 5-ASA in 
HCl buffer (pH 1.2), whereas 18% was released in phosphate buffer (pH 7.4) over a period of 7 h.  In 
rat fecal matter, 87.9% of 5-ASA was released with a half-life of 143.6 min, following first order 
kinetics. The azo conjugate was evaluated for its ulcerogenic potential by Rainsford's cold stress 
method. The ameliorating effect of the azo conjugate and therapeutic efficacy of the carrier system was 
evaluated in TNBS-induced experimental colitis model. The synthesized prodrug was found to be 
equally effective in attenuating the colitis in rats as that of sulfasalazine without the ulcerogenicity of 
5-aminosalicylic acid. 
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Acid-regulation and short chain fatty acids 
 
The proton pump inhibitor omeprazole utilizes the acidic environment of the stomach [57-58]. 
Omeprazole is a prodrug of a sulfonamide that exerts its potent ant-iulcer effects by covalently 
modifying cysteine residues on the luminal side of the proton pump (i.e., H+/K+-ATPase) in the 
oxyntic mucosa of the stomach. This prodrug only exerts its anti-secretory effect in the acidic 
environment of the oxyntic mucosa of the stomach.  
  
Short chain fatty acids 
 
Short chain fatty acids (SCFA), mainly acetate, propionate and butyrate, are produced in the 
colonic environment by action of bacterial fermentation to maintain the normal physiological function 
of the gut. The effects of SCFA include modulation of colonic muscular activity, stimulation of 
electrolyte and fluid uptake and enhancement of blood flow [59-60]. Of the major SCFA, butyrate 
appears to be a preferred oxidative substrate for colonocytes. It also acts to maintain a normal 
phenotype in these cells through repair of damage to DNA and inhibition of apoptosis in normal cells 
and its promotion in colon tumor cells in vitro [59-61] and in vivo rat treated with carcinogen 
azoxymethane [62]. IBD results in SCFA deficiency [63]. SCFA consumed directly in foods or 
beverages are rapidly absorbed in the fore-gut and fail to reach the colon [64]. However, acylated 
maize starch with butyric anhydride was shown to produce resistant starch that increased SCFA in the 
rat gut, apparently through bacterial release of the esterified fatty acid and fermentation of the residual 
starch [65].    
 
Carnitine (β-hydroxy-γ-trimethylaminobutyrate) 
 
Carnitine (β-hydroxy-γ-trimethylaminobutyrate) is obligatory for transport of long-chain fatty acids 
into mitochondria for subsequent β-oxidation [66]; it plays a critical role in energy metabolism of the 
tissues that derive a substantial portion of their metabolic energy from fatty acid oxidation such as 
heart, skeletal muscle, liver [67-68]. Butyrate, a bacterial fermentation product, is beneficial for 
prevention/treatment of ulcerative colitis.  Butyryl-L-carnitine, a butyrate ester of carnitine, may have 
potential for treatment of IBD since butyryl-L-carnitine would supply both butyrate and carnitine. L-
Carnitine is absorbed in the intestinal tract via the carnitine transporter OCTN2 and the amino acid 
transporter ATB. Loss-of-function mutations in OCTN2 may be associated with IBD, suggesting a role 
for carnitine in intestinal/colonic health. In contrast, ATB is upregulated in bowel inflammation [69]  
 
Immunomodulators and Immunosuppressors  
  
Mycophenolate mofetil  
 
Mycophenolate mofetil (MMF, Figure 2) is an ester prodrug of mycophenolic acid, the active 
moiety that gives the drug its immunosuppressive properties [70]. A century ago (1896), Gosio [71] 
Molecules 2008, 13   459 
   
isolated mycophenolic acid from a culture Penicillium species and noted its antibacterial properties.  
Mycophenolic acid decreases de novo synthesis of guanosine nucleotides by reversible inhibition of 
inosine monophosphate dehydrogenase (IMPDH) [72]. This prodrug acts against T and B 
lymphocytes, because these cells depend on the de novo synthesis of purines for proliferation, whereas 
other cell types, such as neutrophils and macrophages, can use salvage pathways [69].  Mycophenolate 
mofetil is unique because of its dual activity as an immunosuppressant, as well as an antimicrobial 
with a novel action against Pneumocystis carinii pneumonitis [73-75].   Mycophenolic acid is known 
to inhibit growth of intestinal smooth muscle and synthesis of fibronectin [76], and may be useful to 
inhibit smooth-muscle hyperplasia and stricture formation in Crohn’s patients.   
 
Figure 2. Molecular structure of the immunomodulator mycophenolate mofetil (MMF). 
N
O
O
O
CH3
O
O
Mycophenolate mofetil  
 
A number of clinical trials [77-80] have suggested a therapeutic role for MMF in patients with 
ulcerative colitis and Crohn’s disease. These controlled trials have shown efficacy of MMF in patients 
with active IBD. Based on these trials, patients with IBD refractory to other IBD therapies 
(corticosteroids, azathioprine or 6-mercaptopurine, methotrexate, and infliximab, monoclonal antibody 
against TNFα) may be treated with MMF in selected circumstance [83]. The development of colitis in 
patients treated with MMF has been described in four renal-transplant recipients [81]. However, these 
patients were receiving high-dose MMF. The development of colitis in these patients may be caused 
by enterohepatic cycling of mycophenolic acid resulting in high colonic concentrations of the 
metabolite [82].  
  
Azathioprine 
 
Azathioprine, a thiopurine prodrug, is another immunosuppressant used in IBD and liver 
transplantation patients [77-78,80,84]. Approximately 1 in 10 patients suffers side effects in response 
to the drug, such as bone marrow toxicity [84]. There is evidence that polymorphisms in the genes 
encoding thiopurine methyltransferase and inosine triphosphate pyrophosphatase predict adverse drug 
reactions to Azathioprine therapy. Furthermore, common genetic polymorphisms in the gene encoding 
methylenetetrahydrofolate reductase may have an indirect impact on thiopurine drug methylation by 
influencing levels of the methyl donor S-adenosylmethionine.  
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Glucocorticosteroids 
 
Corticosteroids are commonly prescribed for treatment of moderate to severe IBD however, 
numerous adverse effects limit their long term use [79]. Budesonide is a nonhalogenated corticosteroid 
with a high affinity for the glucocorticoid receptor. Budesonide is a 1:1 mixture of the epimers 
(22R+22S), which both are rapidly eliminated with a terminal half-life of 2.7±0.6 h [85]. Budesonide is 
extensively metabolized by hydroxylation, while the cytochrome P450 isoenzyme CYP3A4, expressed 
in high amounts in hepatocytes and epithelial cells of the intestinal wall, is the main responsible 
isoenzyme for its rapid elimination. “Budenofalk®” is a slow releasing Budesonide composed of a hard 
gelatin capsule and acid-resistant pellets. The pellets are covered with Eudragit, with a delayed release 
at pH > 6.4. Following ingestion of the capsules more budesonide is available in the region of the 
terminal ileum. [85]. Budesonide-β-D-glucuronide another prodrug is hydrolyzed by colonic bacterial 
and mucosal beta-glucuronidase to librate free budesonide into the colonic milieu. Hydrolysis rates of 
budesonide-β-D-glucuronide in fecal specimens from IBD patients and normal volunteers are similar. 
pH reduction in the colon of IBD patients may inhibit the bacterial hydrolysis of this prodrug.  
 
Antioxidants 
 
Antioxidant status has been described to be compromised in the intestinal mucosa from patients 
with IBD [46-47,86-87]. In vitro studies using enterocytes have also demonstrated the damaging 
effects of exposure to oxidants [88]. Similar studies reveal that the colons of IBD patients produce 
more oxygen free radicals compared with those of control subjects [57,48]. In addition, using a 
chemiluminescence assay, significantly elevated levels of reactive oxygen metabolites were found in 
the actively inflamed mucosa of IBD patients [47,89]. Colitis animals showed an increase in plasma-
oxidized proteins, indicating that DSS induced oxidative stress to be at the systemic level that persisted 
until the end of the treatment [90-94].  Oxidative stress is linked with the stimulation of the immune 
system [18].   
  
Glutathione (GSH)  
 
The endogenous tripeptide glutathione (GSH), is the most important intracellular defense agent in 
mammalian organs, including the gut. GSH is involved in protein folding and protein synthesis, as well 
as in intracellular signaling [90]. Glutathione is the most abundant cellular antioxidant synthesized by 
animal cells. GSH plays an essential role in cell biology and modulates cell responses to redox changes 
associated with the presence of ROS. GSH neutralizes free radicals and ROS toxicity and is essential 
for both the functional and structural integrity of the gut. GSH may be depleted during inflammatory 
illness such as IBD [92, 94] and acetaminophen toxicity [95-97] and this GSH deficiency predisposes 
animals to organ failure and death after an otherwise nonlethal period of hypotension [89, 98]. Indeed 
GSH-deficient mice show severe degradation of the jejunum and colonic mucosa and have body 
weight loss and diarrhea [89]. Depletion of GSH induced enlarged lymphoid aggregates in the intestine 
by recruitment of lymphocytes from the peripheral circulation [99]. The depletion in tissue levels of 
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GSH has been implicated as a component of the inflammatory complications. Supplementation with 
GSH monoethylester has been reported to prevent these lymphoid aggregates [100]. Data showed a 
significant decrease in the blood as well as intestinal tissue levels of GSH in the DSS-induced colitis 
model [94]. GSH plays an essential role in cell biology and modulates cell responses to redox changes 
associated with the presence of ROS. In vivo studies indicated that oxidized colonic mucosal redox 
status stimulated colonic mucosal growth in rats. The data supported that GSH is required to maintain 
normal colonic and plasma cysteine/cystine homeostasis [100].  Because GSH deficiency is associated 
with severe injury such as inflammation and sepsis, treatment strategies that maintain GSH levels may 
decrease the incidence of organ failure.  One strategy for preventing this injury is to boost the levels of 
GSH within the cells. However, GSH is not taken up directly by most cell phenotypes and must first be 
broken down into its component amino acids (cysteine, glutamate, and glycine) by enzymes including 
δ-glutamyltranspeptidase.  
 
Cysteine Prodrugs:  
 
Cysteine an extracellular reducing agent, is a critical substrate for protein synthesis, and the rate-
limiting precursor to GSH [101]. In vivo studies indicated that oxidized colonic mucosal redox status 
stimulated colonic mucosal growth in rats. Therefore, data suggested that GSH is required to maintain 
normal colonic and plasma cysteine /cystine homeostasis. Cysteine can be given orally to increase 
GSH [102] or to chelate trace elements in the gut, thereby decreasing absorption of both cysteine and 
the trace element [103]. 
 
 
 
 
  
 
Cysteine and glutathione prodrugs  
 
Administration of N-acetylcysteine (NAC), a cysteine prodrug, in a rat model of chemically 
induced colitis (TNBS) attenuated acute colitis through increased mucosal GSH levels [104], 
suggesting that cysteine prodrugs may be beneficial in the acute relapse of IBD. Dextran sodium 
sulfate (DSS) treatment of mice mimics IBD in that it provokes inflammation and macrophage 
activation, with subsequent loss of epithelial integrity, and increases luminal Gram-negative 
microbiota [105]. Rebamipide, a drug that inhibits the production of free radicals, was shown to act as 
an anti-inflammatory agent in chronic DSS-induced colitis [106].   
We investigated the efficacy of three different cysteine prodrugs against colitis in DDS-induced 
murine model. 2(RS)-n-Propylthiazolidine-4(R)-carboxylic acid (PTCA), is an L-cysteine prodrug that 
stimulate GSH biosynthesis with a masked sulfhydryl group in the form of a thiazolidine-4-carboxylic 
acid to stabilize it against oxidation  (Figure 3a) [107]. PTCA undergoes ‘demand–pull’ hydrolysis and 
Cysteine (CYSH) + Glutamate (GLU) = δ-glutamylcysteine (G-CLU-CYSH) 
G-GLU-CYSH + Glycine (GLY) = GSH 
2GSH + H2O2 = GSSG + 2H2O 
GSSG + NADPH = 2GSH + NADP  
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release GSH about 20% more efficiently than NAC [108]. 2(RS)-D-ribo-(1’,2’,3’,4’-tetrahydroxy- 
butyl)thiazolidine-4(R)-carboxylic acid, (RibCys) is another L-cysteine prodrug (D-Ribose-L-
cysteine), that like PTCA, can liberate the sulfhydryl-containing amino acid L-cysteine in vivo by non-
enzymatic, hydrolytic dissociation (Figure 3b) [100]. The ester of the carboxylic acid (carrier-linked 
prodrugs) is cleaved by hydrolysis (enzymatic and/or chemical) to liberate the active compound.   
 
Figure 3. Molecular structures of three cysteine and glutathione prodrugs: a) 2(RS)-n-
Propylthiazolidine-4(R)-carboxylic acid (PTCA), an L-cysteine prodrug; b) 2(RS)-D-ribo-
(1’,2’,3’,4’-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) D-Ribose-L-
cysteine and c) L-cysteine-glutathione mixed sulfide (CySSG). 
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L-cysteine-glutathione mixed sulfide (CySSG) is a ubiquitous GSH derivative present in 
mammalian cells and has been suggested to be a depot form of GSH [109].  CySSG, a glutathione 
delivery agent [110] can liberate both GSH and L-cysteine by a glutathione reductase-catalyzed 
reaction with GSH (Figure 3c) [111].   
We have shown that DSS-treated mice develop severe colitis, with decreased GSH concentrations 
in blood, colonic tissue and colon and liver when compared to normal controls [92,94,112]. In 
addition, DSS-treated animals had decreased hematocrits, and elevated inflammatory markers such as 
enzyme Cyclooxygenase (Cox-2), CD68, acute protein serum Amyloid A (SAA), and inflammatory 
cytokines (IL-6, IL-12, TNF-α) including osteopontin (OPN).   
OPN is an important pro-inflammatory glycoprotein secreted by various cell types such as 
macrophages and intestinal epithelial cells [113].  In this study, PTCA-treated mice had significantly 
improved colonic lesions, with higher levels of blood and hepatic GSH, and lower GSSG 
concentrations compared to untreated DSS animals [114]. Based on our findings these antioxidant 
prodrugs reduced disease activity in the colitis. Oral administration of PTCA has been shown to 
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protect against acetaminophen (APAP)-induced hepatic damage and necrosis, as well as GSH and 
cysteine depletion [92,115].   
 
Figure 4. Relative densities of representative western blot analyses (n= 3) indicating 
significant upregulation of Cyclooxygenase (Cox-2) protein expression in colonic tissue 
from colitis mice (DSS) which is normalized with prodrug therapy especially in PTCA 
animals. (DSS)- Represents colitis provided with DSS- supplemented water. PTCA, 
RibCys and CYSSG represent those mice provided with DSS- containing water and 
treated with one of cysteine/GSH prodrugs. (Courtesy of Oz et al, Translational Research 
2007).  
 
 
 
Figure 5. Hepatic concentration of reduced GSH, the major source of gut antioxidant, 
was depleted in colitis animals (DSS) and normalized with prodrug therapy. (GSH was 
measured by HPLC).  
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The results demonstrated a high degree of tissue selectivity in the APAP-induced depletion of GSH 
and cysteine concentrations, and in the effectiveness of PTCA in maintaining and even elevating 
sulfhydryl levels in extrahepatic tissues of APAP-treated mice [116], while the protective effect of 
PTCA was related to prevention of hepatic sulfhydryl depletion. Similarly, oral administration of 
PTCA provided protection against steatohepatitis by attenuating the expression of deleterious pro-
inflammatory and fibrogenic genes in a dietary rat model [117]. Other studies showed that PTCA 
significantly increased GSH biosynthesis in cultured rat lens compared to untreated controls [118], and 
prevented naphthalene-induced experimental cataracts in mice [108].  Thus, our studies indicate that 
PTCA, RibCys and, to a lesser extent, CySSG, provide protection against colitis in this murine model. 
These data also reinforce our previous report describing the novel protective action of PTCA against 
different inflammatory complications including IBD [92,114,117]. 
   
S-adenosylmethionine (SAMe, Adomet) Metabolism and Gut 
 
SAMe, an antioxidant and a GSH precursor is an obligatory intermediate in normal cell physiology 
and in the transsulfuration pathway. SAMe serves as an antioxidant not only because of its role as a 
precursor for GSH biosynthesis, but also because of its capacity to interact directly with ROS. The 
conversion of methionine to SAMe involves transfer of the adenosyl moiety of ATP to the sulfur atom 
of methionine [119]. This process is catalyzed by methionine adenosyltransferase (MAT) in cells 
[120]. The MAT gene is considered one of 33 genes required for survival and MAT is highly 
susceptible to oxidative stress [119]. Besides being a precursor for syntheses of polyamines, choline, 
and GSH, SAMe is also the major biologic methylating agent for DNA, RNA, phospholipids, biologic 
amines, and proteins. SAMe is required for the metabolism of nucleic acids, and for the maintenance 
of the structure and function of membranes [121]. SAMe in stable enteric capsule (cellulose gel) 
synthesized in the form of disulfate tosylate salt and, methacrylic acid copolymer has been shown to 
provide intestinal specific drug delivery systems with pH sensitive swelling and drug release 
properties. Methacrylic-type polymeric prodrugs have been shown to have a defined bioavailability.  
Ulcerative colitis is associated with a selective reduction of n-butyrate oxidation by colonic 
epithelial cells [122, 123]. The reasons for this are not completely understood. Bacterial production of 
anionic sulfide is reported to be increased in the colon of IBD patients and these sulfides can cause 
metabolic damage to colonocytes [123]. Incubation of colonic cell suspensions with sulfide induced a 
significant inhibition of 14CO2 production as compared with controls. Sulfide toxicity in isolated 
colonocytes can be reversed by methyl donors. The addition of S-adenosylmethionine-1,4-butane 
disulfonate to the cell suspension reversed this effect in proximal but not in distal cell incubations, 
suggesting a greater susceptibility of the distal colon to the sulfide effect [124].  
The role of mucosal detoxification of sulfide by thiolmethyltransferase (TMT)-mediated 
methylation was suggested as crucial in protecting the healthy colonic mucosa from the adverse effects 
of luminal sulfide. In the human colon, methylation appears to protect colonic epithelial cells against 
sulfide-induced inhibition of n-butyrate oxidation. Luminal anionic sulfide may contribute to epithelial 
damage in ulcerative colitis [125]. Erythrocyte TMT activity was elevated in patients after 
proctocolectomy for Crohn's disease and Ulcerative Colitis.  In patients with active stage of ulcerative 
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colitis, the mucosal spermidine concentration was increased due to exogenous uptake in comparison 
with patients in remission or in healthy controls. The activities of ornithine decarboxylase and S-
adenosylmethionine decarboxylase, rate-limiting enzymes of polyamine biosynthesis, were lower in 
the patients with ulcerative colitis [125].  These findings in patients suggest that sulfide detoxification 
may be important in the pathogenesis of IBD. Recent investigations show a close interaction between 
endogenous SAMe concentrations (measured by HPLC) and cytokine production in animal models 
[92, 97, 114, 117, 126]. SAMe deficiency increased TNFα production and tissue injury while 
exogenous SAMe supplementation decreased TNFα production in these animals. SAMe 
supplementation significantly improved blood level of GSH, and serum SAA level, as well as pathological scores 
in colitis [92] suggesting a therapeutic value in treatment of IBD. Oral administration of SAMe protected 
against acetaminophen hepatotoxicity in mice [97]. In addition, we reported a therapeutic effect of 
SAMe in oral form against liver injury, elevated liver enzymes aspartate transaminase and alanine 
transaminase and over expression of inflammatory and fibrotic genes (e.g. IL-1β, IL-6,TNFα, MMP3-
9) in a dietary rat model for Nonalcoholic Steatohepatitis (NASH) [117, 126]. We postulate that SAMe 
may also prove to be useful dietary supplement in the treatment of inflammatory disease in patients.    
 
Figure 6. Liver enzymes (ALT and AST) are significantly increased in rats on methionine 
Choline deficient diet (MCD) compared to those fed methionine choline sufficient diet 
(MCS). In contrast, SAMe and PTCA therapy normalize these deleterious enzyme 
activities in rats on an MCD diet (Model for steatohepatitis (NASH).    
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Conclusions 
  
Oral delivery is the most common and preferred route of drug administration although the digestive 
tract exhibits several obstacles to drug delivery including motility and intraluminal pH profiles. 
Currently there is no cure for IBD. Although many treatments have been recommended for IBD, they 
do not treat the cause but are effective only in reducing the inflammation and accompanying symptoms 
[13-20, 49, 52, 85]. Thus, current medical management of IBD consists of anti-inflammatory, 
immunosuppressive agents and other biologics. Since IBD patients undergo prolonged periods of 
treatment, prodrugs are considered as the most practical approach for targeting drugs to the colon in 
IBD patients.  Three classes of prodrugs proven effective in IBD include: (1) anti-inflammatory agents 
(e.g.  5-ASA, azo prodrugs, amino acids) that can result from bacteria changing the function of 
prodrugs or prodrugs treating inflammation which changes the bacteria ecology; (2) 
immunomodulators and immunosuppressants; and (3) antioxidants. Improved drug delivery systems 
are required for drugs currently in use to treat localized diseases of the colon. Therefore, using IBD 
prodrug modalities to target specifically colonic tissue may lower the drug dosage, supply the drug 
only where required by maintaining the drug in its intact form close to the target site, and finally, 
reduce the incidence of systemic side effects in these patients.  
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